June 17, 2021

BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma

Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting p...
Read more
June 17, 2021

Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies

The trial is now fully recruited with a total of 33 patients enrolled with 30 patients in the full dose ONCOS-102 and durvalumab combination in the colorectal cancer cohort &nb...
Read more
June 16, 2021

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical co...
Read more
June 14, 2021

Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxic...
Read more
June 14, 2021

Targovax releases presentations of ONCOS-102 mesothelioma 24-month data

Oslo, Norway, 14 June 2021 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, has released t...
Read more
June 11, 2021

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

Gothenburg, June 11, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such ...
Read more
June 10, 2021

Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival

June 10, 2021 Press release - Regulatory Median overall survival (mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months, comp...
Read more
June 9, 2021

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pi...
Read more
June 8, 2021

CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative im...
Read more
June 7, 2021

Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research

HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing ...
Read more
Older news →